Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NMI 900

Drug Profile

NMI 900

Alternative Names: GSK-1070916; GSK1070916A; NMI-900

Latest Information Update: 20 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer Cancer Research UK; Nemucore Medical Innovations; Oncology Venture A/S
  • Class Antineoplastics; Indoles; Methylurea compounds; Pyrazoles; Pyridines; Pyrroles; Small molecules
  • Mechanism of Action Aurora kinase B inhibitors; Aurora kinase C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Research Myeloid leukaemia
  • No development reported Acute myeloid leukaemia; Breast cancer; Chronic myeloid leukaemia; Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 10 Dec 2022 Early research in Myeloid leukaemia in USA (IV) before December 2022
  • 28 Jul 2022 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Monotherapy) in USA (IV)
  • 28 Jul 2022 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy) in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top